

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Uni-Bio Science Group Ltd.

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 0690)

VOLUNTARY ANNOUNCEMENT

MULTIPLE DRUG CO-DEVELOPMENT AGREEMENT WITH BEIJING SUN-NOVO

The board (“**Board**”) of directors (“**Directors**”) of Uni-Bio Science Group Limited (“**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that after the trading hours of The Stock Exchange of Hong Kong Limited on 1 December 2016, Beijing Genetech Pharmaceutical Co., Limited, a wholly-owned subsidiary of the Company, entered into a multiple drug co-development agreement with Beijing Sun-Novoo Pharmaceutical Research Co., Limited (“**Beijing Sun-Novoo**”), a China-based company engaged in research and development (“**R&D**”), manufacturing and commercialization of pharmaceutical products, to extend the Group’s current R&D capabilities in small molecule drug development. This cooperation includes co-development of various oral anti-diabetes drugs (“**OAD**”) to build a comprehensive diabetes treatment portfolio for the Group, which would represent an all-encompassing strategy in satisfying the unmet needs in treatment of this increasingly prevalent disease.

The first co-development project is to develop high quality Acarbose tablets for treatment of Type 2 diabetes, an emerging and increasingly important diabetes treatment in China. Under this collaboration, Beijing Sun-Novoo is to be responsible for completing the chemistry, manufacturing and control (“**CMC**”) processes and the bioequivalence study of Acarbose, as well as transferring the production technology to the Group. On the other hand, the Group would apply for drug licenses from the China Food and Drug Administration with support from Beijing Sun-Novoo and commercialize the product once it is approved. The project is targeted to start in 2017 and launch sales in the market around 2020-2021.

Acarbose is an oral anti-diabetic drug which belongs to the Alpha-Glucosidase Inhibitors (“**AGI**”) class. It is used to treat Type 2 diabetes and is reimbursed under the National Reimbursement Drug List (“**NRDL**”). In terms of diabetes treatment, AGI is important for the early stage of diabetes. It targets patients with pre-diabetes condition who need to be treated early, and those with post prandial hyperglycemia under control. According to IMS China Data, AGI is uniquely positioned within China’s diabetes guidelines, maintaining around 18% of China’s anti-diabetes drug market in 2012 to 2015, which is especially effective for Asian patients with a high-carbohydrate diet content. Acarbose has the largest market share at 87.8% in China’s AGI market in 2015, which represents a market size of RMB3.4 billion. Meanwhile, the domestic sales revenue of Acarbose increased at a compound annual growth rate of 10.3% from 2012 to 2015, which clearly shows the enormous potential and promising growth opportunities of the drug in the market.

* For identification purpose only

Beijing Sun-Novo is a national high-tech company with international ISO9001:2008 quality management certification. With a 1,200 sq.m. laboratory and a R&D team comprising more than 70 professionals, Beijing Sun-Novo is well-positioned as a high-tech enterprise focusing on the R&D of pharmaceutical technologies and Active Pharmaceutical Ingredient intermediate trading.

The Board believes this co-development arrangement can strengthen the Group's R&D capabilities and ensure a sustainable and successful position in its core strategic therapeutic field to meet the increasing market demand. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge, information and belief, each of Beijing Sun-Novo and its ultimate beneficial owner(s) is a third party independent of and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited).

By order of the Board
Uni-Bio Science Group Limited
TONG Kit Shing
Chairman

Hong Kong, 1 December 2016

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Tong Kit Shing (Chairman) and Mr. Kingsley Leung; and three independent non-executive Directors, namely, Dr. Carl Aslan Jason Morton Firth, Mr. Zhao Zhi Gang and Mr. Chow Kai Ming.